• Home
  • BioVectra Inc.
  • Enabling Commercial Manufacturing for Highly Complex Small Molecule Drugs through Process Engineering and Technological Innovation
Whitepaper
6 Oct 2020

Enabling Commercial Manufacturing for Highly Complex Small Molecule Drugs through Process Engineering and Technological Innovation

PDF 145 kB
Download

This case study presents the successful collaboration between an early-stage company that was struggling with the development of a realistic and economically viable commercial pathway and BioVectra, a CDMO with 50 years of experience.

Read more Show less
Content provided by our supplier

BioVectra Inc.

  • CA
  • 2015
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Primary activities
Biopharmaceutical
View company profile

Other Content from BioVectra Inc. (2)

  • BioVectra Inc. announces a $144.6 million expansion project

    News BioVectra Inc. announces a $144.6 million expansion project

    BioVectra Inc., an Atlantic Canadian Contract Development and Manufacturing Organization (CDMO), announces a five-year, $144.6 million (CAD) expansion project to enhance its Biopharmaceutical capabilities in both Charlottetown, Prince Edward Island and Windsor, Nova Scotia.
    2 Sep 2019
  • BioVectra's CDMO Capabilities

    Video BioVectra's CDMO Capabilities

    BioVectra offers contract development and manufacturing capacity for intermediates and active pharmaceutical ingredients (APIs) from five North American cGMP facilities. We specialize in Microbial Fermentation, Complex Chemistry, Biologics, and Formulation Development.
    2020-10-06